Tuberculosis remains a threat to global health and recent attempts to shorten therapy have
not succeeded mainly due to cases of clinical relapse. This has focussed attention on the …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Antibiotic treatment of tuberculosis has a duration of several months. There is significant
variability of the host immune response and the pharmacokinetic-pharmacodynamic …

Numerous studies show efflux as a universal bacterial mechanism contributing to antibiotic
resistance and also that the activity of the antibiotics subject to efflux can be enhanced by …

Interrupting transmission is an attractive anti-tuberculosis (TB) strategy but it remains
underexplored owing to our poor understanding of the events surrounding transfer of …

Rationale: Carbapenems are recommended for treatment of drug-resistant tuberculosis.
Optimal dosing remains uncertain. Objectives: To evaluate the 14-day bactericidal activity of …

ABSTRACT A milestone in the development of novel antituberculosis drugs is the
demonstration of early bactericidal activity (EBA) in a phase IIa clinical trial. The significant …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are
effective against low-to-intermediate–level isoniazid-resistant strains of Mycobacterium …

“Viable but nonculturable” states of bacteria pose challenges for environmental and clinical
microbiology, but their biological mechanisms remain obscure. Mycobacterium tuberculosis …